MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Search

Harvard Bioscience Inc

Cerrado

SectorSalud

0.55 -5.17

Resumen

Variación precio

24h

Actual

Mínimo

0.55

Máximo

0.58

Métricas clave

By Trading Economics

Ingresos

1.1M

-1.2M

Ventas

141K

21M

Margen de beneficio

-5.978

Empleados

330

EBITDA

1M

1.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+222.58% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.1M

28M

Apertura anterior

5.72

Cierre anterior

0.55

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

151 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Harvard Bioscience Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ene 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 ene 2026, 00:00 UTC

Ganancias

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 ene 2026, 23:47 UTC

Charlas de Mercado

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 ene 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 ene 2026, 23:39 UTC

Charlas de Mercado

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 ene 2026, 23:32 UTC

Charlas de Mercado

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 ene 2026, 22:56 UTC

Adquisiciones, fusiones, absorciones

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 ene 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 ene 2026, 22:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 ene 2026, 22:17 UTC

Charlas de Mercado

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 ene 2026, 22:09 UTC

Ganancias

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 ene 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Announces Positive Profit Alert for 2025

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Citigroup Acting as Financial Advisor to WuXi XDC

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

14 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 ene 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Makes Cash Offer for BioDlink International

14 ene 2026, 21:13 UTC

Charlas de Mercado

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 ene 2026, 20:30 UTC

Charlas de Mercado
Ganancias

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 ene 2026, 20:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 ene 2026, 20:08 UTC

Charlas de Mercado

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 ene 2026, 19:33 UTC

Charlas de Mercado

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 ene 2026, 19:06 UTC

Charlas de Mercado
Ganancias

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Comparación entre iguales

Cambio de precio

Harvard Bioscience Inc Esperado

Precio Objetivo

By TipRanks

222.58% repunte

Estimación a 12 meses

Media 2 USD  222.58%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harvard Bioscience Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.3 / 0.3401Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

No Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

151 / 361 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat